Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Improving Initial Medication Adherence to cardiovascular disease and diabetes treatments in primary care, Pilot trial of a complex intervention

  • Corral-Partearroyo, Carmen|||0000-0001-9517-4916
  • Sánchez-Viñas, Alba|||0000-0001-5020-7534
  • Gil-Girbau, Montserrat|||0000-0002-4396-6492
  • Peñarrubia-María, Maria Teresa
  • Aznar-Lou, Ignacio|||0000-0002-6780-5968
  • Serrano-Blanco, Antoni|||0000-0001-6123-0633
  • Carbonell-Duacastella, Cristina|||0000-0002-8794-5490
  • Gallardo-González, Carmen|||0000-0003-0688-1366
  • Olmos-Palenzuela, María del Carmen
  • Rubio-Valera, Maria|||0000-0003-2856-1697
Introduction: The Initial Medication Adherence (IMA) intervention is a multidisciplinary and shared decision-making intervention to improve initial medication adherence addressed to patients in need of new treatments for cardiovascular diseases and diabetes in primary care (PC). This pilot study aims to evaluate the feasibility and acceptability of the IMA intervention and the feasibility of a cluster-RCT to assess the effectiveness and cost-effectiveness of the intervention. Methods: A 3-month pilot trial with an embedded process evaluation was conducted in five PC centers in Catalonia (Spain). Electronic health data were descriptively analyzed to test the availability and quality of records of the trial outcomes (initiation, implementation, clinical parameters and use of services). Recruitment and retention rates of professionals were analyzed. Twenty-nine semi-structured interviews with professionals (general practitioners, nurses, and community pharmacists) and patients were conducted to assess the feasibility and acceptability of the intervention. Three discussion groups with a total of fifteen patients were performed to review and redesign the intervention decision aids. Qualitative data were thematically analyzed. Results: A total of 901 new treatments were prescribed to 604 patients. The proportion of missing data in the electronic health records was up to 30% for use of services and around 70% for clinical parameters 5 months before and after a new prescription. Primary and secondary outcomes were within plausible ranges and outliers were barely detected. The IMA intervention and its implementation strategy were considered feasible and acceptable by pilot-study participants. Low recruitment and retention rates, understanding of shared decision-making by professionals, and format and content of decision aids were the main barriers to the feasibility of the IMA intervention. Discussion: Involving patients in the decision-making process is crucial to achieving better clinical outcomes. The IMA intervention is feasible and showed good acceptability among professionals and patients. However, we identified barriers and facilitators to implementing the intervention and adapting it to a context affected by the COVID-19 pandemic that should be considered before launching a cluster-RCT. This pilot study identified opportunities for refining the intervention and improving the design of the definitive cluster-RCT to evaluate its effectiveness and cost-effectiveness. Clinical trial registration: ClinicalTrials.gov, identifier NCT05094986.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients

  • Parody-Rua, Elizabeth
  • Bustamante, Alejandro
  • Montaner, Joan
  • Rubio-Valera, María
  • Serrano, David
  • Pérez-Sánchez, Soledad
  • Sánchez-Viñas, Alba
  • Guevara-Cuellar, César
  • Serrano-Blanco, Antoni
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/., [Objectives] Stroke treatment with intravenous tissue-type plasminogen activator (tPA) is effective and efficient, but as its benefits are highly time dependent, it is essential to treat the patient promptly after symptom onset. This study evaluates the cost-effectiveness of a blood biomarker test to differentiate ischemic and hemorrhagic stroke to guide pre-hospital treatment with tPA in patients with suspected stroke, compared with standard hospital management. The standard care for patients suffering stroke consists mainly in diagnosis, treatment, hospitalization and monitoring., [Methods] A Markov model was built with four health states according to the modified Rankin scale, in adult patients with suspected moderate to severe stroke (NIHSS 4-22) within 4.5 hours after symptom onset. A Spanish Health System perspective was used. The time horizon was 15 years. Quality-adjusted life-years (QALYs) and life-years gained (LYGs) were used as a measure of effectiveness. Short- and long-term direct health costs were included. Costs were expressed in Euros (2022). A discount rate of 3% was used. Probabilistic sensitivity analysis and several one-way sensitivity analyses were conducted., [Results] The use of a blood-test biomarker compared with standard care was associated with more QALYs (4.87 vs. 4.77), more LYGs (7.18 vs. 7.07), and greater costs (12,807€ vs. 12,713€). The ICER was 881€/QALY. Probabilistic sensitivity analysis showed that the biomarker test was cost-effective in 82% of iterations using a threshold of 24,000€/QALY., [Conclusions] The use of a blood biomarker test to guide pre-hospital thrombolysis is cost-effective compared with standard hospital care in patients with ischemic stroke., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The present study is part of the Instituto de Salud Carlos III (ISCIII) grant, file number PMP15/00022, and Biomarkers for Initiating Onsite and Faster Ambulance Stroke Therapies (BIOFAST) DTS19/00135. We thank the Research Network on Preventative Activities and Health Promotion (redIAPP) (RD16/0007/0012), the European Regional Development Fund, and the CIBERESP (Centro de Investigación Biomedica en Red de Epidemiología y Salud Pública, CB16/02/00322), for their support in study development. Dr. A. Serrano-Blanco has a personal grant from the PERIS program (SLT006/17/68), Generalitat de Catalunya (Spain), to partially dedicate his time to research during the study period. Dr. Rubio-Valera has a “Miguel Servet” research contract from ISCIII, Ministry of Economy and Competitiveness (Spain) (CP19/00029)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación

Cost-effectiveness analysis of a multiple health behaviour change intervention in people aged between 45 and 75 years, a cluster randomized controlled trial in primary care (EIRA study)

  • Aznar-Lou, Ignacio|||0000-0002-6780-5968
  • Zabaleta del Olmo, Edurne|||0000-0002-5072-8548
  • Casajuana Closas, Marc|||0000-0001-5653-996X
  • Sánchez-Viñas, Alba|||0000-0001-5020-7534
  • Parody-Rúa, Elizabeth
  • Bolíbar, Bonaventura|||0000-0003-4653-9805
  • Iracheta-Todó, Montserrat
  • Bulilete, Oana
  • López Jiménez, Tomàs|||0000-0001-8255-4936
  • Pombo Ramos, Haizea|||0000-0002-8117-3215
  • Martín Miguel, María Victoria
  • Magallon Botaya, Rosa|||0000-0002-5494-6550
  • Maderuelo-Fernandez, Jose-Angel|||0000-0001-7544-8684
  • Motrico, Emma|||0000-0002-0720-567X
  • Bellón Saameño, Juan Ángel|||0000-0002-4268-4979
  • Martí-Lluch, Ruth|||0000-0002-7320-9521
  • Rubio-Valera, Maria|||0000-0003-2856-1697
  • Serrano-Blanco, Antoni|||0000-0001-6123-0633
Multiple health behaviour change (MHBC) interventions that promote healthy lifestyles may be an efficient approach in the prevention or treatment of chronic diseases in primary care. This study aims to evaluate the cost-utility and cost-effectiveness of the health promotion EIRA intervention in terms of MHBC and cardiovascular reduction. An economic evaluation alongside a 12-month cluster-randomised (1:1) controlled trial conducted between 2017 and 2018 in 25 primary healthcare centres from seven Spanish regions. The study took societal and healthcare provider perspectives. Patients included were between 45 and 75 years old and had any two of these three behaviours: smoking, insufficient physical activity or low adherence to Mediterranean dietary pattern. Intervention duration was 12 months and combined three action levels (individual, group and community). MHBC, defined as a change in at least two health risk behaviours, and cardiovascular risk (expressed in % points) were the outcomes used to calculate incremental cost-effectiveness ratios (ICER). Quality-adjusted life-years (QALYs) were estimated and used to calculate incremental cost-utility ratios (ICUR). Missing data was imputed and bootstrapping with 1000 replications was used to handle uncertainty in the modelling results. The study included 3062 participants. Intervention costs were €295 higher than usual care costs. Five per-cent additional patients in the intervention group did a MHBC compared to usual care patients. Differences in QALYS or cardiovascular risk between-group were close to 0 (- 0.01 and 0.04 respectively). The ICER was €5598 per extra health behaviour change in one patient and €6926 per one-point reduction in cardiovascular risk from a societal perspective. The cost-utility analysis showed that the intervention increased costs and has no effect, in terms of QALYs, compared to usual care from a societal perspective. Cost-utility planes showed high uncertainty surrounding the ICUR. Sensitivity analysis showed results in line with the main analysis. The efficiency of EIRA intervention cannot be fully established and its recommendation should be conditioned by results on medium-long term effects. Clinicaltrials.gov . Registered 02 May 2017 - Retrospectively registered The online version contains supplementary material available at 10.1186/s12966-021-01144-5.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Complex multidisciplinary intervention to improve Initial Medication Adherence to cardiovascular disease and diabetes treatments in primary care (the IMA-cRCT study), mixed-methods process evaluation protocol

  • Corral-Partearroyo, Carmen|||0000-0001-9517-4916
  • Sánchez-Viñas, Alba|||0000-0001-5020-7534
  • Gil-Girbau, Montserrat|||0000-0002-4396-6492
  • Peñarrubia-María, Maria Teresa
  • Aznar-Lou, Ignacio|||0000-0002-6780-5968
  • Gallardo-González, Carmen|||0000-0003-0688-1366
  • Olmos-Palenzuela, María del Carmen
  • Rubio-Valera, Maria|||0000-0003-2856-1697
Medication non-initiation, or primary non-adherence, is a persistent public health problem that increases the risk of adverse clinical outcomes. The initial medication adherence (IMA) intervention is a complex multidisciplinary intervention to improve adherence to cardiovascular and diabetes treatments in primary care by empowering the patient and promoting informed prescriptions based on shared decision-making. This paper presents the development and implementation strategy of the IMA intervention and the process evaluation protocol embedded in a cluster randomised controlled trial (the IMA-cRCT) to understand and interpret the outcomes of the trial and comprehend the extent of implementation and fidelity, the active mechanisms of the IMA intervention and in what context the intervention is implemented and works. We present the protocol for a mixed-methods process evaluation including quantitative and qualitative methods to measure implementation and fidelity and to explore the active mechanisms and the interactions between the intervention, participants and its context. The process evaluation will be conducted in primary care centres and community pharmacies from the IMA-cRCT, and participants include healthcare professionals (general practitioners, nurses and community pharmacists) as well as patients. Quantitative data collection methods include data extraction from the intervention operative records, patient clinical records and participant feedback questionnaires, whereas qualitative data collection involves semistructured interviews, focus groups and field diaries. Quantitative and qualitative data will be analysed separately and triangulated to produce deeper insights and robust results. Ethical approval has been obtained from the Research Ethics Comittee (CEIm) at IDIAP Jordi Gol (codeCEIm 21/051 P). Findings will be disseminated through publications and conferences, as well as presentations to healthcare professionals and stakeholders from healthcare organisations. .
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Over 40 years (1981-2023) assessing stigma with the Community Attitudes to Mental Illness (CAMI) scale, a systematic review of its psychometric properties

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Doval Dieguez, Eduardo|||0000-0001-8416-160X
  • Bernadàs, Albert
  • Angarita-Osorio, Natalia|||0000-0001-8925-2754
  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Evans-Lacko, Sara
  • Thornicroft, Graham
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Rubio-Valera, Maria|||0000-0003-2856-1697
The Community Attitudes to Mental Illness (CAMI) scale measures social stigma towards people with mental illness. Although it has been used worldwide, the psychometric properties of the CAMI have not been systematically reviewed. The main aim of this study was to systematically review the psychometric properties of the different versions of the CAMI more than 40 years after of its publication. A systematic search was conducted in MEDLINE, PsycINFO, Web of Science, and EMBASE from 1981 (year of publication) to 2023 (present). A double review was performed for eligibility, data extraction, and quality assessment. A total of 15 studies enrolling 10,841 participants were included. The most frequently reported factor structure comprises 3 or 4 factors. Overall, the internal consistency seems adequate for the global scale (α ≥ 0.80), except for CAMI-10 (α = 0.69). Internal consistency of the subscales are not supported, with authoritarianism being the weakest factor (α = 0.27 to 0.68). The stability over time of the total scale has been assessed in the CAMI-40, CAMI-BR, and CAMI-10 (r ≥ 0.39). Few studies have assessed the temporal stability of the CAMI subscales. Most of the correlations with potentially related measures are significant and in the expected direction. The 3 and 4 factor structure are the most widely reported in the different versions of the CAMI. Even though reliability and construct validity are acceptable, further item refinement by international consensus seems warranted more than 40 years after the original publication. PROSPERO identification number: CRD42018098956. The online version contains supplementary material available at 10.1186/s13643-023-02230-4.